706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study
Silverberg J, Calimlim B, Fuxench Z, Altman K, Bensimon A, Liu J, Bunick C. 706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study. British Journal Of Dermatology 2024, 191: ljae266.080. DOI: 10.1093/bjd/ljae266.080.Peer-Reviewed Original ResearchPatient support programAtopic dermatitisItch improvementSkin clearanceOral Janus kinase inhibitorPatient experiencePhase 3 clinical trialsTreating moderate-to-severe ADEffect of upadacitinibMultiple phase 3 clinical trialsModerate-to-severe ADJanus kinase inhibitorsClinical trial resultsPatient-reported experiencesDecreased quality of lifeEvaluate patient experiencePatient-reported outcomesTopical corticosteroidsPatient ageCross-sectional analysisQuality of lifeUpadacitinib dosesKinase inhibitorsUpadacitinibTreatment durationEarly and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
Silverberg J, Gooderham M, Paller A, Deleuran M, Bunick C, Gold L, Hijnen D, Calimlim B, Lee W, Teixeira H, Hu X, Zhang S, Yang Y, Grada A, Platt A, Thaçi D. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). American Journal Of Clinical Dermatology 2024, 25: 485-496. PMID: 38528257, PMCID: PMC11070400, DOI: 10.1007/s40257-024-00853-4.Peer-Reviewed Original ResearchPatient Global ImpressionModerate-to-severe atopic dermatitisPatients treated with upadacitinibPatient-reported outcomesGlobal ImpressionAtopic dermatitisWeek 1Skin symptomsQuality of lifeTreating moderate-to-severe atopic dermatitisPhase III monotherapy trialsPhase III randomized clinical trialsWeek 8Baseline to week 1Pruritus Numerical Rating ScaleScoring Atopic Dermatitis indexEffect of upadacitinibOral selective Janus kinaseAtopic Dermatitis indexAssessed patient-reported outcomesMinimal clinically important differenceNumerical rating scaleDermatology Life Quality IndexPatient-Oriented Eczema MeasureChronic inflammatory disease